dc.contributor.author |
Reig-López, Javier
|
es_ES |
dc.contributor.author |
M. Cuquerella-Gilabert
|
es_ES |
dc.contributor.author |
Bandín-Vilar, Enrique
|
es_ES |
dc.contributor.author |
Merino-Sanjuán, Matilde
|
es_ES |
dc.contributor.author |
Mangas-Sanjuán, Victor
|
es_ES |
dc.contributor.author |
García-Arieta, Alfredo
|
es_ES |
dc.date.accessioned |
2024-07-30T18:04:33Z |
|
dc.date.available |
2024-07-30T18:04:33Z |
|
dc.date.issued |
2024-06 |
es_ES |
dc.identifier.issn |
0939-6411 |
es_ES |
dc.identifier.uri |
http://hdl.handle.net/10251/206887 |
|
dc.description.abstract |
[EN] The characterization of the time course of ibuprofen enantiomers can be useful in the selection of the most sensitive analyte in bioequivalence studies. Physiologically based pharmacokinetic (PBPK) modelling and simulation represents the most efficient methodology to virtually assess bioequivalence outcomes. In this work, we aim to develop and verify a PBPK model for ibuprofen enantiomers administered as a racemic mixture with different immediate release dosage forms to anticipate bioequivalence outcomes based on different particle size distributions. A PBPK model incorporating stereoselectivity and non-linearity in plasma protein binding and metabolism as well as R-to-S unidirectional inversion has been developed in Simcyp (R). A dataset composed of 11 Phase I clinical trials with 54 scenarios (27 per enantiomer) and 14,452 observations (7129 for R-ibuprofen and 7323 for S-ibuprofen) was used. Prediction errors for AUC0-t and Cmax for both enantiomers fell within the 0.8-1.25 range in 50/54 (93 %) and 42/54 (78 %) of scenarios, respectively. Outstanding model performance, with 10/10 (100 %) of Cmax and 9/10 (90 %) of AUC0-t within the 0.9-1.1 range, was demonstrated for oral suspensions, which strongly supported its use for bioequivalence risk assessment. The deterministic bioequivalence risk assessment has revealed R-ibuprofen as the most sensitive analyte to detect differences in particle size distribution for oral suspensions containing 400 mg of racemic ibuprofen, suggesting that achiral bioanalytical methods would increase type II error and declare non-bioequivalence for formulations that are bioequivalent for the eutomer. |
es_ES |
dc.language |
Inglés |
es_ES |
dc.publisher |
Elsevier |
es_ES |
dc.relation.ispartof |
European Journal of Pharmaceutics and Biopharmaceutics |
es_ES |
dc.rights |
Reconocimiento - No comercial (by-nc) |
es_ES |
dc.subject |
Bioequivalence |
es_ES |
dc.subject |
Ibuprofen |
es_ES |
dc.subject |
PBPK |
es_ES |
dc.subject |
Racemase |
es_ES |
dc.subject |
Stereoselectivity |
es_ES |
dc.title |
Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers |
es_ES |
dc.type |
Artículo |
es_ES |
dc.identifier.doi |
10.1016/j.ejpb.2024.114293 |
es_ES |
dc.rights.accessRights |
Abierto |
es_ES |
dc.description.bibliographicCitation |
Reig-López, J.; M. Cuquerella-Gilabert; Bandín-Vilar, E.; Merino-Sanjuán, M.; Mangas-Sanjuán, V.; García-Arieta, A. (2024). Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers. European Journal of Pharmaceutics and Biopharmaceutics. 199. https://doi.org/10.1016/j.ejpb.2024.114293 |
es_ES |
dc.description.accrualMethod |
S |
es_ES |
dc.relation.publisherversion |
https://doi.org/10.1016/j.ejpb.2024.114293 |
es_ES |
dc.type.version |
info:eu-repo/semantics/publishedVersion |
es_ES |
dc.description.volume |
199 |
es_ES |
dc.identifier.pmid |
38641229 |
es_ES |
dc.relation.pasarela |
S\523073 |
es_ES |